{"id":42166,"date":"2013-12-24T00:00:00","date_gmt":"2013-12-23T23:00:00","guid":{"rendered":"https:\/\/techma.bakertilly.es\/ultimas-inversiones-en-diagnostico-de-enfermedades\/"},"modified":"2025-03-12T11:25:19","modified_gmt":"2025-03-12T10:25:19","slug":"ultimas-inversiones-en-diagnostico-de-enfermedades","status":"publish","type":"post","link":"https:\/\/techma.bakertilly.es\/en\/ultimas-inversiones-en-diagnostico-de-enfermedades\/","title":{"rendered":"Latest investments in \"disease diagnostics"},"content":{"rendered":"

Biotech companies are developing new test systems to detect diseases as early as possible. Venture capital is no stranger to this trend and in December alone, more than 15 venture capital deals were completed in the first half of 2008. funding<\/strong>in a field dominated by the venture capital<\/strong> pharmaceutical companies.<\/span><\/p>\n

\"The disease diagnosis activity has been in full swing throughout the year, with more than 100 operations of funding<\/strong> throughout the year. The most successful ones have been around for quite a few years because it is a sector that requires patience from investors, but these companies have demonstrated with facts their capacity to bring a product to the market\", analyses Diego Gutierrez from\u00a0Abra Invest.<\/span><\/a><\/span><\/strong><\/span><\/p>\n

<\/p>\n

The companies that stand out for having attracted the largest amount of investment were:<\/span><\/p>\n

Vermillion $74M for diagnosis of women's diseases<\/strong><\/span><\/p>\n

Vermillion,<\/span><\/a><\/span>\u00a0located in Austin USA and founded in 1993, has been awarded a financing round<\/strong> of 1TP2Q17.3M in December 2013 led by the fund\u00a0Oracle Investment Management,<\/span><\/a><\/span>\u00a0a specialist in the health sector. The company is dedicated to the development and commercialisation of high-value markers and diagnostic tests that address unmet needs in oncology, gynaecology and women's health.<\/span><\/p>\n

Biodesix $67.6M for lung cancer screening<\/strong><\/span><\/p>\n

Biodesix<\/span><\/a><\/span>\u00a0offers\u00a0VeriStrat,<\/span><\/a><\/span>\u00a0a serum protein test that helps physicians choose therapy for patients with advanced non-small cell lung cancer (NSCLC). The test is now commercially available and provides oncologists with the information needed to select between erlotinib and single-agent chemotherapy for patients with advanced lung cancer. The tests are processed in the CLIA-certified laboratory.\u00a0Biodesix '<\/span><\/a><\/span>and the results are presented in less than 72 hours. In December 2013 it closed one round<\/strong> $8.3M of which $4.3M are new funds and another $4M from the conversion of convertible bonds.<\/span><\/p>\n

Rheonix $42.1M for Biomedical Devices<\/strong><\/span><\/p>\n

Rheonix, Inc.<\/span><\/a><\/span>. operates as a biomedical device company. Its products include CARD (Chemistry and Reagent Device) to miniaturise and automate new and existing assays in various fields. Its products and technologies are used in human\/veterinary, in vitro diagnostics, food\/water analysis, SNP analysis for customised medicine applications, homeland security\/defence applications, process control and final product quality control and tissue culture analysis in a research or production context. It has closed in December 2013 a round<\/strong> of $12M provided by\u00a0Rand Capital\u00a0<\/span><\/a><\/span>and\u00a0Cayuga Venture Fund,\u00a0<\/span><\/a><\/span>which already contributed another $6M in a series A round in 2010.<\/span><\/p>","protected":false},"excerpt":{"rendered":"

Biotech companies are developing new systems to test for diseases as early as possible. Venture capital is no stranger to this trend and in December alone more than 15 financing operations were made, in a field dominated by corporate venture capital from pharmaceutical companies.<\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2277],"tags":[171,172],"sectores":[],"tipo-contenido":[2260],"class_list":["post-42166","post","type-post","status-publish","format-standard","hentry","category-multiplos-de-empresas-cotizadas","tag-capital-riesgo","tag-venture-capital","tipo-contenido-noticias"],"acf":[],"_links":{"self":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/comments?post=42166"}],"version-history":[{"count":0,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/posts\/42166\/revisions"}],"wp:attachment":[{"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/media?parent=42166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/categories?post=42166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tags?post=42166"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/sectores?post=42166"},{"taxonomy":"tipo-contenido","embeddable":true,"href":"https:\/\/techma.bakertilly.es\/en\/wp-json\/wp\/v2\/tipo-contenido?post=42166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}